RDY Stock Recent News
RDY LATEST HEADLINES
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #AVT03--Alvotech and Dr. Reddy's announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.
SHANGHAI , Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection.
Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the anticipated Revlimid revenue drop, RDY's new product launches in biosimilars and GLP-1 segments are expected to offset losses, driving future growth. RDY's current P/E ratio of 17.7x is near historical lows; a conservative 23x PE, which is equal to the peer median and slightly lower than the median of the historical range.
Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ET Company Participants Richa Periwal – Head-Investor Relations and Analytics Erez Israeli – Chief Executive Officer M V Narasimham – Chief Financial Officer Conference Call Participants Kunal Dhamesha – Macquarie Neha Manpuria – Bank of America Amey Chalke – JM Financial Bino Pathiparampil – Elara Capital Surya Narayan Patra – PhillipCapital Damayanti Kerai – HSBC Tushar Manudhane – Motilal Oswal Financial Services Saion Mukherjee – Nomura Foram Parekh – Bank of Baroda Capital Market Anubhav Agrawal – UBS Vishal Manchanda – Systematix Shashank Krishnakumar – Emkay Global Operator Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presenta
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY25--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.
PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's launches comprehensive menopause support program and training for employees during menopause awareness month.
BENGALURU, India & HYDERABAD, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma.